Gallant Pet, Inc.

San Diego, CA · Founded 2018 · Biotech · Private

Ready-to-use stem cell therapies for pets

Claim this profile

Follows are private to you and power your alerts

Updated · gallant.com

Sector
Biotech
Headquarters
San Diego, CA
Founded
2018
Latest Form D
$10.2M, Jul 2025
Total capital
$42.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$42.6M
3 Form D · last Jul 2025
16 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
3
15 pending · first 2020
Rank in peer group#339 of 1449

Capital timeline

2019202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $42.6M1st Form D$7M2nd Form D$25.5M
2019202120232025FEDERAL ↑EQUITY ↓Cumulative $42.6M1st Form D$7M2nd Form D$25.5M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$10.2M
  • Private capital raisedForm D · SEC · 2nd filing$25.5M
  • Private capital raisedForm D · SEC · 1st filing$7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#339 · top 23%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Linda BlackResearcherExecutive Officer, DirectorLinked by 2 patents
  • Aaron HirschhornExecutive Officer, DirectorNamed in SEC Form D filings
  • Aaron SchachtDirectorNamed in SEC Form D filings
  • Darryl RawlingsDirectorNamed in SEC Form D filings
  • Davis BrimerExecutive Officer, DirectorNamed in SEC Form D filings
  • Doug DrewDirectorNamed in SEC Form D filings
Show all 10 people
  • James RatiganDirectorNamed in SEC Form D filings
  • Misti UshioDirectorNamed in SEC Form D filings
  • Richard JenningsDirectorNamed in SEC Form D filings
  • Teymour Boutros-GhaliDirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 18
Show all 18 patent records
  • Uterine-derived Regenerative Cell Compositions And Uses ThereofDec 16, 2025 · US 12,497,594Granted
  • Uterine-derived Regenerative Cell Compositions And Uses ThereofMar 4, 2025 · US 12,241,088Granted
  • Primed Uterine-derived Regenerative Cell Compositions And Uses ThereofJan 16, 2025 · Application 18707117Pending
  • Methods For Optimizing Reproductive Tissue Derived Cell Yield And Viability For Clinical ApplicationsOct 24, 2024 · Application 18262069Pending
  • Systemic, Allogenic Stem Cell Therapies For Treatment Of Diseases In AnimalsMar 31, 2022 · Application 17302747Pending
  • Uses Of Trehalose In Cell SuspensionsAug 19, 2021 · Application 17302633Pending
  • Viable Cell Compositions, And Methods Related To SameDec 10, 2020 · Application 16738870Pending
  • Vial Useable In Tissue Extraction ProceduresMay 19, 2020 · US 10,653,397Granted
  • Viable Cell Compositions, And Methods Related To SameNov 23, 2017 · Application 15471578Pending
  • Systemic, Allogenic Stem Cell Therapies For Treatment Of Diseases In AnimalsJan 19, 2017 · Application 15281291Pending
  • Uses Of Trehalose In Cell SuspensionsMar 31, 2016 · Application 14869006Pending
  • Methods For Optimizing Reproductive Tissue Derived Cell Yield And Viability For Clinical ApplicationsApplication 63139031Pending
  • Primed Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication 63263550Pending
  • Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication 63022302Pending
  • Uterine-derived Regenerative Cell Compositions And Uses Thereof For Clinical ApplicationsApplication 63263548Pending
  • Methods For Optimizing Reproductive Tissue Derived Cell Yield And Viability For Clinical ApplicationsApplication PCTUS2022070219Pending
  • Primed Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication PCTUS2022048067Pending
  • Uterine-derived Regenerative Cell Compositions And Uses ThereofApplication PCTUS2021031148Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .